Literature DB >> 7799529

Spasmolytic effect of the NK2-receptor-selective antagonist MEN 10,627 in rat small intestine.

M Tramontana1, C A Maggi, S Evangelista.   

Abstract

The effect of activation of tachykinin NK2-receptors on gastrointestinal propulsion was studied in vivo in conscious rats. The selective NK2-receptor agonist [beta Ala8]NKA-(4-10) produced an atropine-resistant specific increase of the small intestinal transit measured by the charcoal method. This effect was restricted to the small intestine since gastric emptying was not affected by [beta Ala8]NKA-(4-10). The newly developed polycyclic peptide NK2-receptor antagonist MEN 10,627 produced a dose-dependent inhibition of this stimulated transit. The spasmolytic effect of MEN 10,627 was highly selective because it did not affect stimulated intestinal transit induced by equieffective doses of carbachol and reserpine. These findings indicate that MEN 10,627 is a valuable tool for assessing the role of NK2-receptors in intestinal propulsive activity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7799529     DOI: 10.1254/jjp.65.281

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  4 in total

1.  Tachykinin receptors mediate atropine-resistant rat duodenal reflex contractions in vivo.

Authors:  S Giuliani; M Tramontana; A Lecci; C A Maggi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996 Aug-Sep       Impact factor: 3.000

2.  Tachykinin NK(2) receptors and enhancement of cholinergic transmission in the inflamed rat colon: an in vivo motility study.

Authors:  F Carini; A Lecci; M Tramontana; S Giuliani; C A Maggi
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

3.  Tachykinins influence interdigestive rhythm and contractile strength of human small intestine.

Authors:  M Lördal; E Theodorsson; P M Hellström
Journal:  Dig Dis Sci       Date:  1997-09       Impact factor: 3.199

Review 4.  Tachykinin NK2 receptor antagonists for the treatment of irritable bowel syndrome.

Authors:  Alessandro Lecci; Angela Capriati; Carlo Alberto Maggi
Journal:  Br J Pharmacol       Date:  2004-03-22       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.